Teenagers Are Taking New Weight-Loss Drugs, but the Science Is Far from Settled
Wegovy and similar weight-loss medications are becoming widely prescribed for teenagers with obesity, but little is known about their long-term effects
Weight-loss drugs didn't curb health costs within two years
Drugs like Wegovy may trim your waistline but not medical costs, according to an analysis of U.S. health insurance claims shared with Reuters.
Competition will make weight-loss drugs better, cheaper and bigger
A mong the many newcomers to the business of weight-loss drugs is Hims & Hers, an American e-pharmacy better known for hawking remedies for erectile dysfunction and hair loss. Since May it has offered its own version of Wegovy,
Opinion
New weight loss drugs raise questions of access, costs
New, popular injectable weight loss drugs — GLP-1 drugs — are highly effective at reducing obesity and, probably, the health risks posed by obesity. Yet the drugs are so expensive that insurers are often choosing between two bad options: restricting access or raising consumer costs.
Behind Hims & Hers’ weight loss drug campaign in the New York Times
Hims & Hers is taking a more serious approach to its latest campaign. The telehealth company, which is best known for its lighthearted sexual health and hair loss ads, has bought a series of print ads in the New York Times drawing attention to the obesity epdemic. Hims & Hers began selling weight loss drugs in 2023.
Opinion
Stop the games. Make NC healthier by expanding weight-loss drug coverage | Opinion
Despite the benefits of such medicines, like Wegovy, Saxenda and Zepbound, many people who could most benefit from them can’t get them. | Opinion
US Medicaid Programs Say Cost a Key Factor for Weight-Loss Drug Coverage, Survey Finds
The survey of the 50 states and the District of Columbia found that just 12 Medicaid programs covered the drugs to treat obesity as of July 2024 with some limits on use. Half of the states without coverage said they are considering adding them or evaluating their coverage,
Study finds high costs, few benefits associated with GLP-1 weight loss drugs
A new study from a pharmacy benefit manager is casting doubt on the benefits of GLP-1 drugs used for weight loss, finding they are associated with a high cost of care with little benefit beyond dropping pounds.
More state Medicaid programs consider covering GLP-1 drugs
While all state Medicaid programs cover GLP-1 agonists for type 2 diabetes, it’s much less common for them to cover the drugs for obesity. Currently, just 13 state Medicaid programs cover GLP-1s for obesity.
STAT4m
In the era of GLP-1 drugs, demand for bariatric surgery plunges
The findings spell an uncertain future for hospitals and clinics that derive a significant portion of their revenues from ...
New anti-obesity drug shows promise in preventing heart failure related to type 2 diabetes
A University of Alberta pharmacology researcher has discovered that a new experimental anti-obesity drug improves diastolic ...
The Economist1d
It’s not just obesity. Drugs like Ozempic will change the world
First the drugs tackled diabetes. Then, with just an injection a week, they took on obesity. Now they are being found to ...
The Breakthrough Drug to Conquer Addiction: Ozempic?
Early data suggests GLP-1 drugs, renowned for their ability to assist in weight loss, may have a powerful effect on treating ...
Adolescents treated for obesity with GLP-1 drugs had lower risk of suicidal thoughts, study finds
“We know that generally, with and without obesity, mental health and suicidality is ... who has done similar work analyzing ...
The ‘Peak Obesity’ Illusion
America’s obesity rate looks to be plateauing—again.